Quick Answer
ImmunityBio, Inc. reported Operating Income of -$256.03 million for fiscal year 2025.
ImmunityBio, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$256.03M | +25.6% |
| 2024 | -$344.18M | +5.0% |
| 2023 | -$362.25M | -3.1% |
| 2022 | -$351.30M | -6.4% |
| 2021 | -$330.28M | -49.5% |
| 2020 | -$220.88M | -41.4% |
| 2019 | -$156.25M | -58.8% |
| 2018 | -$98.39M | +0.7% |
| 2017 | -$99.12M | +20.4% |
| 2016 | -$124.50M | +47.9% |
| 2015 | -$238.88M | -4184.8% |
| 2014 | -$5.58M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$55.63M | +30.7% | +22.0% |
| June 30, 2025 | -$71.28M | +28.2% | -10.6% |
| March 31, 2025 | -$64.43M | +32.3% | +19.7% |
| September 30, 2024 | -$80.25M | -0.1% | +19.2% |
| June 30, 2024 | -$99.33M | -16.7% | -4.3% |
| March 31, 2024 | -$95.20M | +14.7% | -18.8% |
| September 30, 2023 | -$80.14M | +11.7% | +5.9% |
| June 30, 2023 | -$85.14M | -6.9% | +23.7% |
- ImmunityBio, Inc. showed an increase of +25.6% in Operating Income compared to the prior fiscal year.
- Over the 2014–2025 period, ImmunityBio, Inc.’s operating income has declined by 4492.4% (from -$5.58 million to -$256.03 million).
- The most recent figure is from ImmunityBio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: